Oncology
Latest news
915 articles · 20 / page
Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05
The DESTINY-Breast05 trial demonstrates that Trastuzumab Deruxtecan significantly improves invasive disease-free survival compared to Trastuzumab Emtansine in patients with residual HER2-positive early breast cancer, establishing a new pote
Disitamab Vedotin Plus Gemcitabine Shows Promise as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer
A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.
Tailoring Systemic Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Evidence by Disease Volume and Timing of Metastasis
A living network meta-analysis refines treatment strategies for mHSPC subgroups, favoring triplet therapy in synchronous high-volume cases and ARPI doublet therapy in others.
Refining Prostate Cancer Risk Prediction in Men of African Ancestry: Integrating Pathogenic Variants, Polygenic Scores, and Family History
This study identifies key germline variants and demonstrates how combining genetic data with family history improves personalized prostate cancer risk assessment in men of African ancestry, guiding future screening strategies.
Personalizing Breast Cancer Screening: Insights from the WISDOM Trial on Risk-Based vs Annual Mammography
The WISDOM trial shows risk-based breast cancer screening using genetic and clinical data as a safe alternative to annual mammography, tailoring screening frequency by individual risk without increasing advanced cancer rates.
Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status
A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.
Broad Genetic Testing Reveals Hidden Breast Cancer Risk in Women Without Family History
The WISDOM trial found that 3.1% of women without breast cancer carried pathogenic variants in key susceptibility genes, many outside existing testing guidelines.
Simple vs Radical Hysterectomy: Balancing Survival Outcomes and Quality of Life in Early Cervical Cancer
Evidence suggests simple hysterectomy with pelvic lymphadenectomy may offer similar survival outcomes to radical hysterectomy in early-stage cervical cancer, with fewer adverse events and better short-term quality of life.
Breast Surgery in Metastatic Breast Cancer: Local Control Without Survival Benefit
Randomised trials show breast surgery improves local disease control but not overall survival in de novo metastatic breast cancer.
Postmenopausal Hormone Therapy: Balancing Endometrial Protection and Cancer Risk
Updated evidence shows unopposed estrogen increases endometrial hyperplasia risk, while combined regimens offer better protection.
Trastuzumab Deruxtecan plus Pertuzumab Becomes First-Line Standard for HER2‑Positive Metastatic Breast Cancer: Clinical Implications of the DESTINY‑Breast09 Approval
The FDA has approved trastuzumab deruxtecan with pertuzumab as first-line therapy for unresectable or metastatic HER2‑positive breast cancer after DESTINY‑Breast09 showed a large PFS benefit versus standard THP; safety and maintenance strat
CBT‑I in Cancer Survivors: Small Subjective Gains, Unclear Objective Benefits — What the 2025 Cochrane Review Tells Clinicians
A 2025 Cochrane review of 21 RCTs (2431 participants) finds cognitive behavioural therapy for insomnia (CBT‑I) yields modest improvements in self‑reported insomnia and sleep quality in people with cancer versus inactive controls or aerobic
Intraperitoneal Chemotherapy for Gastric Cancer: Promising Survival Signals but Very Low‑Certainty Evidence
A Cochrane review of nine RCTs (829 patients) found low‑certainty signals that intraperitoneal chemotherapy (mainly HIPEC) may improve overall survival in high‑risk and metastatic gastric cancer, but evidence is very uncertain due to bias,
Acupuncture for Cancer-Related Insomnia: Limited, Low-Certainty Benefits Compared with Sham or No Treatment; Inferior to CBT‑I
A 2025 Cochrane review (5 RCTs, 402 patients, mainly women with breast cancer) finds very low- to moderate-certainty evidence that acupuncture delivers small, uncertain sleep diary benefits versus sham or inactive controls and is probably l
FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations
The FDA approved once‑daily niraparib plus abiraterone acetate and prednisone for adults with deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (CSPC), based on rPFS and interim overall survi
Breast Cancer Index in Premenopausal HR+ Disease: Prognostic Confirmed, Predictive Role for OFS-Intensification Context-Dependent
Two large prospective‑retrospective analyses confirm BCI as a robust prognostic biomarker in premenopausal HR+ breast cancer; its HOXB13/IL17BR (H/I) component predicted benefit from adding ovarian function suppression versus tamoxifen alon
Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy
Integrated analysis shows a 2013 NEN classification change inflated EOCRC counts in the youngest adults, while independent molecular studies reveal distinct hypermutated and non‑hypermutated EOCRC subtypes with higher MSI/TMB and pathway-sp
Proton Pump Inhibitor Use and Survival Outcomes in Newly Diagnosed Glioblastoma: An Evidence-Based Review
Proton pump inhibitor use, particularly potent ALDH1A1-activating PPIs, is associated with worse survival in newly diagnosed glioblastoma, highlighting the need for cautious use and further mechanistic research.
Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma
A Bayesian network meta-analysis integrating health‑related quality of life and overall survival across first‑line trials in advanced hepatocellular carcinoma shows atezolizumab plus bevacizumab provides the most favorable combined patient‑
Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis
A patient‑level and trial‑level meta‑analysis of nine RCTs (5,114 patients) shows that adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves pathologic complete response and event‑free survival in triple‑negative breast c
Browse by specialty
Open language-specific specialty feeds and department pages.